Compare · ASND vs NVS
ASND vs NVS
Side-by-side comparison of Ascendis Pharma A/S (ASND) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASND and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 21.8x ASND ($13.04B).
- Over the past year, ASND is up 18.1% and NVS is up 24.3% - NVS leads by 6.2 points.
- ASND has hit the wire 7 times in the past 4 weeks while NVS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Ascendis Pharma A/S
- Novartis AG
- Price
- $205.00-2.62%
- $146.72-1.58%
- Market cap
- $13.04B
- $284.62B
- 1M return
- -16.63%
- +0.87%
- 1Y return
- +18.11%
- +24.31%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 25
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ASND
- EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)
- Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)
- EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)
- Amendment: New insider Smith Scott Thomas claimed ownership of 4,017 units of Ordinary Shares (SEC Form 3)
- Director Bienaime Jean Jacques bought $95,120 worth of Ordinary Shares (400 units at $237.80) (SEC Form 4)
- SEC Form SD filed by Ascendis Pharma A/S
- Citigroup initiated coverage on Ascendis Pharma with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S
- Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG